Symptom Management and Palliative Care Research Opportunities
Research in symptom management and palliative care goes far beyond traditional end-of-life issues and extends across the cancer continuum. NCI is making efforts to close research gaps through funding opportunities, training, and partnerships and has added a page to its cancer.gov Web site that will assist symptom management and palliative care investigators in locating and pursuing new funding opportunities in these areas.
NCI's Palliative Care Working Group coordinates the page http://cancer.gov/researchfunding/
announcements/symptommanagement, which lists areas of encouraged research from various NIH institutes and centers in one place. With this page, researchers can identify the latest funding opportunities in symptom management and palliative care.
NCI also offers a range of postdoctoral training opportunities in these areas, which are posted at http://cancer.gov/cancertraining. Established investigators, junior faculty, and postdoctoral candidates from underrepresented groups can visit http://cancer.gov/minorityopportunities for grant opportunities.
An Invitation to Help Chart the Future of Cancer Research
Each year, cancer researchers, health care providers, and advocates have an opportunity to participate in charting the future of cancer research. The Nation's Investment in Cancer Research has become even more important to accelerate and focus our efforts to eliminate the suffering and death due to cancer, considering the limited resources and continued urgency to achieve our goals.
The document articulates priorities and outlines strategic directions for NCI and the National Cancer Program. It is used to communicate to the president and Congress what is needed to move cancer research forward, ensure that research is translated into evidence-based interventions, and move interventions into public health programs and medical practice. If you have not received the solicitation for input on the Nation's Investment in Cancer Research for Fiscal Year 2006, please e-mail firstname.lastname@example.org.
NCI Director's Seminar Series to Highlight Biotechnology
Carl B. Feldbaum, president of the Biotechnology Industry Organization (BIO) will be the next featured speaker of the NCI Director's Seminar Series. The talk, "Biotechnology and NCI: Partners in Bringing Patients the Next Generation of Cancer Therapy," will take place on March 19 at 2 p.m. in Masur Auditorium on the NIH campus. As with other speakers in this series, Mr. Feldbaum is a nationally known leader involved in work that directly affects NCI's challenge goal to eliminate the suffering and death due to cancer by 2015. BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers, and related organizations in all 50 states and in 33 nations.
Mr. Feldbaum will provide an overview of the biotechnology industry, including its accomplishments in the development of cancer therapies, how the industry operates, and how it is financed. He will also address the importance of collaboration among industry, government, and academia and will discuss issues such as conflict of interest and the taxpayer's fair rate of return on the investment in research. The meeting will be webcast live at http://videocast.nih.gov. For more information visit http://cancer.gov/directorscorner.
C-Change Releases Survey on Cancer Attitudes
At a March 3 Washington, D.C. meeting hosted by former President George H. W. Bush and Senator Diane Feinstein, a national organization released a survey showing that Americans fear cancer more than any other major disease. The organization, C-Change, found that virtually every American has been touched by cancer and that only 28 percent know that 70 percent of cancers are preventable. The survey also found that 42 percent of Americans believe that if someone develops cancer, he or she will most likely die from it, although 82 percent reported knowing a survivor. Regarding clinical trial participation, approximately 80 percent said they would enroll in a trial if they were diagnosed with cancer, in stark contrast to the 3 to 5 percent of cancer patients who currently participate. C-Change was originally formed as the National Dialogue on Cancer in 1998. C-Change Board Chair Dr. LaSalle Leffall, Jr. said the organization has evolved from a group driven by dialogue into one seeking action.